SCHEMBL770026

SCHEMBL770026

COc1ccc(-n2cnc3cc(N(Cc4ccc(C(C)C)cc4)S(=O)(=O)c4ccc(C)cc4)ccc32)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 9/20 0.53
CNR1 P21554 7/20 0.53
HTT P42858 2/20 0.53
GAA P10253 1/20 0.53
ALOX12 P18054 1/20 0.53
LMNA P02545 4/20 0.51
ALDH1A1 P00352 4/20 0.51
NPSR1 Q6W5P4 1/20 0.51
BMP1 P13497 1/20 0.44
MAPT P10636 3/20 0.43
HPGD P15428 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KEAP1 Q14145 1/20 0.43
NFE2L2 Q16236 1/20 0.43
TP53 P04637 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
FGFR1 P11362 1/20 0.42
NR3C1 P04150 2/20 0.42
PGR P06401 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL769874 0.81 MAPT (0.51) HTTGAAALOX12LMNAALDH1A1
SCHEMBL770107 0.79 MAPT (0.50) HTTLMNAALDH1A1MAPTHPGD
SCHEMBL770037 0.77 KMT2A (0.51) CNR2CNR1ALOX12LMNAALDH1A1
SCHEMBL15201290 0.74 FGFR1 (0.59) HTTGAALMNAALDH1A1MAPT
SCHEMBL769873 0.72 MAPT (0.54) HTTGAAALOX12LMNAALDH1A1
SCHEMBL769872 0.72 MAPT (0.56) HTTGAAALOX12LMNAALDH1A1
SCHEMBL769761 0.71 NPC1 (0.64) HTTGAAALOX12LMNAALDH1A1
SCHEMBL15064400 0.71 CNR2 (1.00) CNR2CNR1LMNAALDH1A1NPSR1
SCHEMBL15064731 0.71 CNR2 (1.00) CNR2CNR1
SCHEMBL15201869 0.69 ALDH1A1 (0.57) HTTGAAALOX12LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629170-B2 Anti-viral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2014-01-14 US claimed
EP-1988776-B1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES INC (US) 2012-08-08 EP claimed
US-20110172281-A1 Anti-Viral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2011-07-14 US claimed
US-7977365-B2 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2011-07-12 US claimed
EP-2291184-A2 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION Siga Technologies, Inc. (US) 2011-03-09 EP claimed
US-7872037-B2 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2011-01-18 US claimed
WO-2010036399-A2 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES, INC. (US) 2010-04-01 WO claimed
US-20080300265-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION SIGA TECHNOLOGIES INC. (US) 2008-12-04 US claimed
EP-1988776-A2 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES, INC. (US) 2008-11-12 EP claimed
US-20070254934-A1 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. 2007-11-01 US claimed
WO-2007103111-A2 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES, INC. (US) 2007-09-13 WO claimed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8629170-B2 Anti-viral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2014-01-14 US disclosed
US-7872037-B2 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. (US) 2011-01-18 US disclosed
US-20080300265-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION SIGA TECHNOLOGIES INC. (US) 2008-12-04 US disclosed
US-20080300265-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION SIGA TECHNOLOGIES INC. (US) 2008-12-04 US disclosed
US-20070254934-A1 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. 2007-11-01 US disclosed
US-20070254934-A1 Antiviral drugs for treatment of arenavirus infection SIGA TECHNOLOGIES, INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172281-A1 Anti-Viral Drugs for Treatment of Arenavirus Infection GK, GALK1, KLK7 CNR2 4854/4885CNR1 4754/4885HTT 2339/4885
US-20070254934-A1 Antiviral drugs for treatment of arenavirus infection GK, GALK1, GZMB CNR2 4841/4885CNR1 4705/4885HTT 2258/4885
US-20080300265-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION GK, MAVS, ZC3HAV1 CNR2 4828/4885CNR1 4649/4885HTT 2352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.